The global HER-2 Negative Breast Cancer Market is estimated to be valued at US$ 13,873.7 Mn in 2023 and is expected to exhibit a CAGR of 10.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
HER-2 negative breast cancer lacks expression and/or amplification of human epidermal growth factor receptor 2 (HER2). Treatment for HER-2 negative breast cancer includes chemotherapy, hormonal therapy, radiation therapy, targeted therapy and surgery. The need for improved and targeted treatment drives the growth of this market.
Market key trends:
One of the key trends in the HER-2 Negative Breast Cancer Market is the development and approval of novel targeted therapies. Companies are focusing on development of targeted monoclonal antibodies and tyrosine kinase inhibitors (TKIs) to address unmet needs. For example, tucatinib, a tyrosine kinase inhibitor developed by Seattle Genetics, was approved by the US FDA in 2021 for treatment of advanced HER2-positive breast cancer in combination with trastuzumab and capecitabine. It acts as an oral, small molecule inhibitor of HER2. Similarly, trastuzumab deruxtecan, an antibody-drug conjugate, developed by Daiichi Sankyo was approved in 2019 for the treatment of patients with HER2-positive breast cancer. It selectively delivers chemotherapy inside HER2-positive cancer cells.
Segment Analysis
The global HER-2 negative breast cancer market is segmented based on treatment type and end-user. Based on treatment type, the market is segmented into chemotherapy, targeted therapy, immunotherapy, surgery and radiation therapy, hormonal therapy, and others. Among these, the chemotherapy segment dominated the market in 2022 due to the frequent usage of chemotherapy drugs such as taxanes, anthracyclines and combinations for HER-2 negative breast cancer treatment.
Key Takeaways
The Global Her-2 Negative Breast Cancer Market Size is expected to witness high growth at a CAGR of 10.1% over the forecast period, due to increasing prevalence of breast cancer worldwide.
Regional analysis
North America dominated the global market in 2022 and is estimated to maintain its dominance over the forecast period. This is attributed to the increasing prevalence of breast cancer and developed healthcare infrastructure in the region. Asia Pacific is anticipated to exhibit fastest growth over the forecast period due to growing awareness about early detection of breast cancer and increasing healthcare expenditures.
Key players
Key players operating in the HER-2 negative breast cancer market are Pfizer Inc., Novartis AG, Merck & Co. Inc., GSK PLC, AstraZeneca, Eli Lilly and Company, and Bristol-Myers Squibb Company (Celgene Corporation), among others. Pfizer Inc. dominated the global market with its chemotherapy drugs such as docetaxel and paclitaxel indicated for breast cancer treatment.
Read more: https://www.ukwebwire.com/her-2-negative-breast-cancer-market-insights-trends/
Breast cancer is cancer that forms in the cells of the breasts.After skin cancer, breast cancer is the most common cancer diagnosed in women in the United States.
Breast cancer can occur in both men and women, but it's far more common in womenhttps://www.egypttales.com/2021/10/health-breast-cancer.html
